Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept versus tacrolimus in newly diagnosed AChR-positive generalized myasthenia gravis
ChiCTR2400084715Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myasthenia gravis (MG) comparing Telitacicept group with Tacrolimus group (2 arms). Primary endpoints: Effect of corticosteroid reduction at Week 24 and Treatment-related adverse reactions. Planned start May 2024; status: not yet recruiting.
02
Drugs
telitacicepttacrolimus
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2400084715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084715.